The results may provide novel insights into the role of CD44-/CD24- tumor cells in delayed breast cancer metastasis and into the potential use of CD44-/CD24- cells as a biomarker to predict survival and metastasis in breast cancer patients. This evidence concerns the gene CD44 and neoplasm.